Sarah Cannon Research Institute (SCRI) has acquired Clinical Development Group (CDG), a clinical trial consulting firm based in New Haven, CT. The acquisition expands SCRI’s capabilities in global clinical and regulatory planning, trial project management, and provides access to therapeutic expertise, key opinion leadership and academic relationships.   Additionally, SCRI has opened an office in Cambridge, MA and several experienced members of CDG will join the SCRI Development Innovations busin...